Renal and metabolic effects of SGLT-2i and DPP-4i according to basal estimated glomerular filtration rate: Analysis from GIOIA, an observational prospective study.
In the GIOIA study, users of both SGLT-2i and DPP-4i improved glycometabolic control, after 12 months, independently from baseline eGFR levels. Moreover, both classes led to a significant decrease in eGFR in participants with eGFR ≥ 90 ml/min/1.73 m2 and no deterioration in case of mild impairment of renal function.
['Longo|Miriam|M|', 'Scappaticcio|Lorenzo|L|', 'Maiorino|Maria Ida|MI|', 'De Nicola|Luca|L|', 'Bellastella|Giuseppe|G|', 'Esposito|Katherine|K|']
D003924:Diabetes Mellitus, Type 2 D054873:Dipeptidyl-Peptidase IV Inhibitors D005919:Glomerular Filtration Rate D006801:Humans D007668:Kidney D011446:Prospective Studies D000077203:Sodium-Glucose Transporter 2 Inhibitors
SGLT-2i DPP-4i eGFR Kidney function Type 2 diabetes